**Supplementary Material**

**CSF Apolipoprotein E and Milliplex inflammatory marker assays**

CSF apolipoprotein E (apoE) levels were assessed using the Milliplex APOMAG-62k human apolipoprotein cardiovascular disease multiplex assay (EMD Millipore, Billerica, MA). The multiplex assay was performed in 96-well plates. The plate was wetted with 150 μL wash buffer for 10 min and left to decant. 25 μL standards or samples, 25 μL beads, and 25 μL assay buffer were added and incubated overnight at 4°C. The beads were washed three times, after which 50 μL biotinylated detection antibody cocktail was added and incubated at room temperature for 1 h. 50 μL Streptavidin- Phycoerythrin were added and further incubated at room temperature for 30 min. Lastly, we washed the beads three times, added 150 μL sheath fluid and obtained readings on Luminex® instrumentation.

We used the same protocol using Milliplex HCYTMAG60PMX29BK xMap kit to assay CSF levels of 29 immune/inflammatory markers including EGF, Eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β and VEGF.

**Supplementary Table 1.** Association of PREVENT-AD CSF immune/inflammatory markers with pathological stages. We used linear regression models to assess the relationship between CSF marker levels and pathological stages as a categorical variable. All models were adjusted for age, gender, and APOE ε4 carrier status. Represented βs are for stage-wise comparisons of marker levels. p-values are shown uncorrected for multiple comparisons. Markers for which the names are **bolded** were significantly different in Stage 1 or Stage 2 versus Stage 0 (+p ≤ 0.1; \*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.005), although only one of these (VCAM-1) survived adjustment for multiple comparisons (not shown). ‡Data were standardized as z-scores.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Marker‡** | **Stage 1 versus 0** | **Stage 2 versus 0** | **SNAP versus 0** | **Stage 2 versus 1** |
| Granulocyte Colony-Stimulating Factor | β = 0.37  p = 0.26 | β = 0.62  p = 0.13 | β = 1.09  **p = 0.003\*\*\*** | β = 0.25  p = 0.61 |
| Granulocyte-Macrophage Colony-Stimulating Factor | β = -0.45  p = 0.22 | β = -0.03  p = 0.94 | β = 0.47  p = 0.18 | β = 0.43  p = 0.41 |
| Interferon α2 | β = -0.34  p = 0.31 | β = 0.18  p = 0.66 | β = 0.60  p = 0.09+ | β = 0.52  p = 0.28 |
| Interferon Gamma-Induced Protein 10 | β = -0.24  p = 0.42 | β = 0.28  p = 0.45 | β = 1.23  **p = 3.59E-4\*\*\*** | β = 0.52  p = 0.23 |
| Monocyte Chemoattractant Protein 1 | β = -0.40  p = 0.20 | β = 0.51  p = 0.19 | β = 0.42  p = 0.23 | β = 0.91  **p = 0.05\*** |
| Macrophage Inflammatory Protein 1 beta | β = -0.07  p = 0.85 | β = -0.17  p = 0.75 | β = -0.08  p = 0.88 | β = -0.10  p = 0.86 |
| **Interleukin 12p40** | β = -0.83  **p = 0.02\*** | β = -0.11  p = 0.81 | β = 0.20  p = 0.56 | β = 0.72  p = 0.17 |
| **Interleukin 12p70** | β = -0.84  **p = 0.03\*** | β = -0.53  p = 0.19 | β = 0.85  **p = 0.01\*\*** | β = 0.31  p = 0.55 |
| **Interleukin 15** | β = -0.60  **p = 0.04\*** | β = 0.38  p = 0.31 | β = 1.20  **p = 0.001\*\*\*** | β = 0.97  **p = 0.02\*** |
| Interleukin 6 | β = 0.43  p = 0.40 | β = 0.25  p = 0.59 | β = 0.59  p = 0.13 | β = -0.18  p = 0.78 |
| **Interleukin 8** | β = -0.66  **p = 0.03\*** | β = 0.28  p = 0.46 | β = 0.94  **p = 0.004\*\*\*** | β = 0.94  **p = 0.04\*** |
| Interleukin 16 | β = -0.05  p = 0.89 | β = 0.47  p = 0.32 | β = 1.25  **p = 0.004\*\*\*** | β = 0.52  p = 0.32 |
| Interleukin 10 | β = 0.10  p = 0.85 | β = 0.24  p = 0.64 | β = 0.11  p = 0.80 | β = 0.14  p = 0.84 |
| Interleukin 1 Receptor Antagonist | β = 0.16  p = 0.64 | β = -0.19  p = 0.65 | β = -0.39  p = 0.28 | β = -0.35  p = 0.48 |
| C-Reactive Protein | β = -0.24  p = 0.54 | β = -0.51  p = 0.34 | β = 0.47  p = 0.32 | β = -0.27  p = 0.65 |
| Serum Amyloid A | β = -0.36  p = 0.30 | β = -0.44  p = 0.36 | β = 0.34  p = 0.43 | β = -0.08  p = 0.89 |
| **Intercellular Adhesion Molecule 1** | β = -0.57  p = 0.10+ | β = 0.98  **p = 0.05\*** | β = 1.12  **p = 0.01\*\*** | β = 1.55  **p = 0.01\*\*** |
| **Vascular Cell Adhesion Molecule 1** | β = -0.75  p = **0.02\*** | β = 1.29  **p = 4.85E-3\*\*\*** | β = 1.27  **p = 0.001\*\*\*** | β = 2.04  **p = 9.42E-5\*\*\*** |
| Vascular Endothelial Growth Factor | β = -0.26  p = 0.46 | β = -0.04  p = 0.94 | β = 0.18  p = 0.63 | β = 0.22  p = 0.70 |
| Apolipoprotein E | β = -0.23  p = 0.45 | β = 0.12  p = 0.74 | β = 1.26  **p = 2.26E-4\*\*\*** | β = 0.36  p = 0.41 |

**Supplementary Table 2.** Association of PREVENT-AD CSF inflammatory biomarkers and AD biomarkers. We assessed the relationship of apoE protein and 19 CSF immune marker levels with typical CSF AD biomarkers using multivariate linear regression models. All models used age, gender, and APOE ε4 carrier status as covariates. P-values were adjusted using the false discovery rate method. ‡Data were standardized as z-scores. In all, with adjustment for multiple comparisons, 9 of 19 immune markers and apoE showed a significant relationship with one or more specified AD biomarkers.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker**‡ | **Aβ1-42** | | **Transformed t-*tau*** | | **Transformed P181-*tau*** | | **Transformed t-*tau*/Aβ1-42** | |
| **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** |
| **apoE** | β =101.33  p = 1.14E-4\*\*\* | **p = 2.28E-3\*\*\*** | β = 0.22  p = 1.65E-7\*\*\* | **p = 1.10E-6\*\*\*** | β = 0.20  p = 4.32E-8\*\*\* | **p = 4.32E-7\*\*\*** | β = 0.52  p = 5.97E-4\*\*\* | **p = 2.98E-3\*\*\*** |
| **GCSF** | β = 6.99  p = 0.80 | p = 0.80 | β = 0.09  p = 0.05\* | p = 0.09+ | β = 0.06  p = 0.12 | p = 0.19 | β = 0.28  p = 0.08+ | p = 0.16 |
| **GMCSF** | β = 33.99  p = 0.23 | p = 0.33 | β = 0.06  p = 0.23 | p = 0.33 | β = 0.06  p = 0.14 | p = 0.19 | β = 0.11  p = 0.49 | p = 0.58 |
| **IFNα2** | β = 48.29  p = 0.08+ | p = 0.15 | β = 0.15  p = 7.04E-4\*\*\* | **p = 2.01E-3\*\*\*** | β = 0.13  p = 6.10E-4\*\*\* | **p = 2.03E-3\*\*\*** | β = 0.41  p = 0.01\*\* | **p = 0.02\*** |
| **IL10** | β = 8.60  p = 0.78 | p = 0.80 | β = 0.06  p = 0.26 | p = 0.33 | β = 0.07  p = 0.1+ | p = 0.17 | β = 0.21  p = 0.23 | p = 0.38 |
| **IL12P40** | β = 61.51  p = 0.05\* | p = 0.14 | β = 0.09  p = 0.06+ | p = 0.12 | β = 0.07  p = 0.13 | p = 0.19 | β = 0.16  p = 0.34 | p = 0.48 |
| **IL12P70** | β = 84.59  p = 0.01\*\* | **p = 0.03\*** | β = 0.05  p = 0.25 | p = 0.33 | β = 0.08  p = 0.04\* | p = 0.08+ | β = -3.99E-3  p = 0.98 | p = 0.98 |
| **IL15** | β = 98.04  p = 2.29E-4\*\*\* | **p = 2.29E-3\*\*\*** | β = 0.23  p = 1.90E-8\*\*\* | **p = 3.79E-7\*\*\*** | β = 0.21  p = 7.28E-9\*\*\* | **p = 1.46E-7\*\*\*** | β = 0.54  p = 3.93E-4\*\*\* | **p = 2.62E-3\*\*\*** |
| **IL1RA** | β = -36.03  p = 0.18 | p = 0.28 | β = -0.06 p = 0.18 | p = 0.27 | β = -0.05  p = 0.20 | p = 0.25 | β = -0.12  p = 0.42 | p = 0.56 |
| **IL6** | β = 34.22  p = 0.26 | p = 0.35 | β = 0.07  p = 0.12 | p = 0.20 | β = 0.07  p = 0.08+ | p = 0.14 | β = 0.21  p = 0.18 | p = 0.33 |
| **IL8** | β = 75.14  p = 5.91E-3\*\* | **p = 0.03\*** | β = 0.17  p = 8.48E-5\*\*\* | **p = 2.83E-4\*\*\*** | β = 0.13  p = 1.45E-3\*\*\* | **p = 1.45E-3\*\*\*** | β = 0.42  p = 0.01\* | **p = 0.02\*** |
| **IP10** | β = 50.94  p = 0.07+ | p = 0.15 | β = 0.12  p = 0.01\* | **p = 0.02\*** | β = 0.10  p = 0.02\* | **p = 0.04\*** | β = 0.31 p = 0.05\* | p = 0.12 |
| **MCP1** | β = 28.28  p = 0.31 | p = 0.39 | β = 0.15  p = 1.5E-3\*\*\* | **p = 2.62E-3\*\*\*** | β = 0.12  p = 2.12E-3\*\*\* | **p = 0.01\*\*** | β = 0.44  p = 0.01\*\* | **p = 0.02\*** |
| **VEGF** | β = 15.07  p = 0.58 | p = 0.68 | β = 0.01  p = 0.76 | p = 0.84 | β = 0.01  p = 0.82 | p = 0.91 | β = -0.01  p = 0.97 | p = 0.98 |
| **MIP1β** | β = 12.68  p = 0.69 | p = 0.77 | β = 0.01  p = 0.80 | p = 0.84 | β = -0.01  p = 0.89 | p = 0.94 | β = 0.02  p = 0.90 | p = 0.98 |
| **IL16** | β = 62.84  p = 0.04\* | p = 0.14 | β = 0.21  p = 9.96E-6\*\*\* | **p = 4.98E-5\*\*\*** | β = 0.16  p = 4.00E-4\*\*\* | **p = 1.60E-3\*\*\*** | β = 0.65  p = 1.87E-4\*\*\* | **p = 1.87E-3\*\*\*** |
| **CRP** | β = 65.20  p = 0.03\* | p = 0.13 | β = 2.19E-3  p = 0. 97 | p = 0.97 | β = 2.56E-3  p = 0.96 | p = 0.96 | β = -0.19  p = 0.30 | p =0.46 |
| **SAA** | β = 43.53  p = 0.17 | p = 0.28 | β = 0.06  p = 0.30 | p = 0.36 | β = 0.05  p = 0.34 | p = 0.40 | β = 0.15  p = 0.44 | p =0.56 |
| **sICAM1** | β = 57.25  p = 0.06+ | p = 0.15 | β = 0.21  p = 1.40E-5\*\*\* | **p = 5.60E-5\*\*\*** | β = 0.17  p = 2.11E-4\*\*\* | **p = 1.05E-3\*\*\*** | β = 0.57  p = 1.24E-3\*\*\* | **p = 4.97E-3\*\*\*** |
| **sVCAM1** | β = 54.02  p = 0.07+ | p = 0.15 | β = 0.24  p = 1.44E-7\*\*\* | **p = 1.10E-6\*\*\*** | β = 0.21  p = 1.50E-6\*\*\* | **p = 9.98E-6\*\*\*** | β = 0.68  p = 5.36E-5\*\*\* | **p =1.07E-3\*\*\*** |

**Supplementary Table 3.** Association of CSF markers and pathological Stages in the ADNI-1 cohort. We used linear regression models to assess the relationship between CSF marker levels and pathological stages as a categorical variable. 237 (90 healthy controls, 147 with MCI) subjects were included in this analysis. All models were adjusted for age, gender, APOE ε4 carrier status, and clinical diagnostic group at baseline. Represented β are for stage-wise comparisons of marker levels. p-values are shown after adjusting for multiple comparisons using the False Discovery rate procedure. ‡ Transformed data

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Marker‡** | **Stage 1 versus 0** | **Stage 2 versus 0** | **SNAP versus 0** | | **Stage 2 versus 1** |
| **AXL Receptor Tyrosine Kinase** | β = -0.46  **pFDR=0.02** | β = 0.43  **pFDR =0.04** | β = 1.78  pFDR=1.15E-6 | | β = 0.88  **pFDR=2.81E-8** |
| CD40 antigen | β = -0.19  pFDR=0.32 | β = 0.45  **pFDR=0.04** | β = 1.22  pFDR=4.33E-4 | | β = 0.64  **pFDR=4.80E-5** |
| **Interleukin-3** | β = -0.45  **pFDR=0.03** | β = -0.12  pFDR=0.56 | β = 0.88  pFDR=0.01 | | β = 0.33  **pFDR=0.04** |
| Macrophage Colony-Stimulating Factor 1 | β = -0.16  pFDR=0.40 | β = 0.59  **pFDR=0.01** | β = 1.13  pFDR=1.13E-3 | | β = 0.75  **pFDR=3.31E-6** |
| **Heparin-Binding EGF-Like Growth Factor** | β = -0.42  **pFDR=0.03** | β = 0.35  pFDR=0.11 | β = 1.19  pFDR=6.31E-4 | | β = 0.77  **pFDR=1.87E-6** |
| Hepatocyte Growth Factor | β = 0.12  pFDR=0.56 | β = 0.91  **pFDR=1.59E-5** | β = 1.11  pFDR=1.22E-3 | | β = 0.80  **pFDR=7.18E-7** |
| **Transforming Growth Factor alpha** | β = -0.49  **pFDR=0.02** | β = 0.35  pFDR=0.12 | β = 0.58  pFDR=0.1 | | β = 0.84  **pFDR=6.72E-7** |
| **Vascular Endothelial Growth Factor** | β = -0.64  **pFDR=0.002** | β = 0.25  pFDR=0.21 | β = 1.21  pFDR=3.37E-4 | | β = 0.89  **pFDR=1.18E-8** |
| hFatty Acid-Binding Protein | β = -0.25  pFDR=0.16 | β = 0.75  **pFDR=1.25E-4** | β = 0.75  pFDR=0.02 | | β = 1.01  **pFDR=1.98E-10** |
| **Lectin-Like Oxidized LDL Receptor 1** | β = -0.36  **pFDR=0.05** | β = 0.43  **pFDR=0.04** | β = 1.45  pFDR=4.11E-5 | | β = 0.79  **pFDR=4.39E-7** |
| **Angiotensin-Converting Enzyme** | β = -0.44  **pFDR=0.03** | β = 0.37  pFDR=0.10 | β = 1.11  pFDR=1.24E-3 | | β = 0.80  **pFDR=7.18E-7** |
| **Tissue Factor** | β = -0.39  **pFDR=0.03** | β = 0.67  **pFDR=3.82E-4** | β = 1.49  pFDR=1.81E-5 | | β = 1.06  **pFDR=1.24E-11** |
| **Chromogranin-A** | β = -0.54  **pFDR=0.01** | β = 0.51  **pFDR=0.01** | β = 1.20  pFDR=4.33E-4 | | β = 1.05  **pFDR=1.15E-10** |
| **Fibroblast Growth Factor 4** | β = 0.45  **pFDR=0.03** | β = 0.06  **pFDR=0.75** | β = -0.58  pFDR=0.09 | | β = -0.38  **pFDR=0.02** |
| **Cystatin-C** | β = 0.40  **pFDR= 0.03** | β = -0.68  **pFDR=3.63E-4** | β = -1.39  pFDR=4.11E-5 | | β = -1.07  **pFDR=1.05E-11** |
| **Matrix Metalloproteinase-3** | β = -0.40  **pFDR=0.03** | β = 0.40  **pFDR=0.06** | β = 1.26  pFDR=3.37E-4 | β = 0.81  **pFDR=5.19E-7** | |
| Osteopontin | β = 0.00  pFDR=0.99 | β = 0.84  **pFDR=8.72E-5** | β = 0.50  pFDR=0.14 | | β = 0.84  **pFDR=4.33E-7** |
| **Tissue Inhibitor of Metalloproteinases1** | β = -0.52  **pFDR=0.01** | β = -0.21  pFDR=0.31 | β = 0.71  pFDR=0.03 | | β = 0.32  **pFDR=0.04** |
| **Tumor Necrosis Factor Receptor2** | β = -0.38  **pFDR=0.03** | β = 0.54  p**FDR=0.01** | β = 1.31  pFDR=1.13E-4 | | β = 0.92  **pFDR=2.41E-9** |
| **Vascular Cell Adhesion Molecule-1** | β = -0.37  p**FDR=0.04** | β = 0.18  pFDR=0.33 | β = 1.20  pFDR=3.37E-4 | | β = 0.55  **pFDR=2.45E-4** |
| Apolipoprotein E | β = -0.35  pFDR = 0.06 | β = 0.61  **pFDR=0.003** | β = 1.17  pFDR= 6.31E-4 | | β = 0.96  **pFDR=2.85E-9** |
| **Clusterin (apolipoprotein-J)** | β = -0.51  **pFDR =0.01** | β = 0.19  pFDR=0.32 | β = 1.35  pFDR=1.83E-4 | | β = 0.70  **pFDR=8.82E-6** |
| **Trefoil Factor 3** | β = -0.53  **pFDR = 0.01** | β = 0.11  pFDR=0.56 | β = 0.83  pFDR=9.46E-3 | | β = 0.63  **pFDR=2.34E-5** |

**Supplementary Table 4.** Association of ADNI-1 CSF markers with the t-tau/Aβ1-42. We assessed relation of CSF marker levels with the typical composite AD biomarker t-tau/Aβ1-42 using multivariate linear regression models. The analysis included 237 individuals (90 healthy controls, 147 with MCI). Models were adjusted for age, gender, APOE ε4 carrier status, and clinical diagnostic group. P-values were adjusted for multiple comparisons using the False Discovery Rate Procedure (\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.005). ‡Transformed data

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Marker**‡ | **Aβ1-42** | | **Transformed t-*tau*** | | **Transformed P181-*tau*** | | **Transformed t-*tau*/Aβ1-42** | |
| **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** | **Uncorrected** | **FDR adjusted** |
| AXL Receptor Tyrosine Kinase | β = 5.43  p = 0.07 | p = 0.19 | β = 0.20  p = 1.62E-14 | p = 3.73E-14 | β= 0.11  p = 8.67E-5 | p = 1.17E-4 | β= 0.20  p = 8.47E-7 | p = 1.62E-6 |
| CD 40 antigen | β = 4.02  p = 0.21 | p = 0.34 | β = 0.21  p = 4.50E-14 | p = 9.41E-14 | β= 0.15  p = 2.91E-7 | p = 6.69E-7 | β= 0.21  p = 3.54E-7 | p = 8.14E-7 |
| Interleukin-3 | β = 8.87  p = 4.09E-3 | p = 0.05 | β = 0.11  p = 1.39E-4 | p = 1.52E-4 | β= 0.06  p = 0.04 | p = 0.04 | β= 0.07  p = 0.10 | p = 0.11 |
| Macrophage Colony-Stimulating Factor 1 | β = 2.07  p = 0.51 | p = 0.59 | β = 0.18  p = 6.37E-11 | p = 9.77E-11 | β= 0.14  p = 1.02E-6 | p = 2.13E-6 | β= 0.19  p = 5.82E-6 | p = 9.56E-6 |
| Matrix Metalloproteinase-3 | β = 2.98  p = 0.34 | p = 0.46 | β = 0.16  p = 4.70E-9 | p = 6.01E-9 | β= 0.12  p = 8.36E-6 | p = 1.28E-5 | β= 0.16  p = 1.08E-4 | p = 1.46E-4 |
| Osteopontin | β = -6.67  p = 0.03 | p = 0.11 | β = 0.20  p = 5.32E-14 | p = 1.02E-13 | β= 0.05  p = 0.05 | p = 0.06 | β= 0.27  p = 2.30E-11 | p = 1.32E-10 |
| Tissue Inhibitor of Metalloproteinases 1 | β = 8.81  p = 0.01 | p = 0.05 | β = 0.03  p = 0.30 | p = 0.30 | β= 0.02  p = 0.57 | p = 0.57 | β= -0.02  p = 0.70 | p = 0.70 |
| Tumor Necrosis Factor Receptor 2 | β = 1.48  p = 0.65 | p = 0.68 | β = 0.22  p = 1.49E-14 | p = 3.73E-14 | β= 0.15  p = 8.77E-8 | p = 3.36E-7 | β= 0.23  p = 2.31E-8 | p = 6.65E-8 |
| Vascular Cell Adhesion Molecule-1 | β = 5.42  p = 0.10 | p = 0.22 | β = 0.14  p = 3.07E-6 | p = 3.54E-6 | β= 0.10  p = 1.34E-3 | p = 1.62E-3 | β= 0.13  p = 3.62E-3 | p = 4.38E-3 |
| Fibroblast Growth Factor 4 | β = -6.20  p = 0.05 | p = 0.16 | β = -0.08  p = 6.40E-3 | p = 6.69E-3 | β= -0.04  p = 0.14 | p = 0.14 | β= -0.05  p = 0.26 | p = 0.27 |
| Heparin-Binding EGF-Like Growth Factor | β = 5.28  p = 0.09 | p = 0.20 | β = 0.21  p = 1.25E-14 | p = 3.60E-14 | β = 0.14  p = 2.07E-7 | p = 6.19E-7 | β = 0.20  p = 6.17E-7 | p = 1.29E-6 |
| Hepatocyte Growth Factor | β = -7.01  p = 0.02 | p = 0.11 | β = 0.19  p = 2.28E-12 | p = 4.04E-12 | β = 0.17  p = 3.72E-10 | p = 1.71E-9 | β = 0.26  p = 1.12E-10 | p = 4.28E-10 |
| Transforming Growth Factor alpha | β = 2.54  p = 0.40 | p = 0.52 | β = 0.18  p = 1.20E-10 | p = 1.72E-10 | β = 0.12  p = 5.55E-6 | p = 9.12E-6 | β = 0.18  p = 9.52E-6 | p = 1.37E-5 |
| Vascular Endothelial Growth Factor | β = 8.58  p = 0.01 | p = 0.05 | β = 0.22  p = 3.35E-15 | p = 1.10E-14 | β = 0.14  p = 1.57E-6 | p = 2.77E-6 | β = 0.19  p = 4.94E-6 | p = 8.74E-6 |
| Apolipoprotein E | β = 1.52  p = 0.62 | p = 0.68 | β = 0.22  p = 3.70E-16 | p = 1.67E-15 | β = 0.14  p = 2.15E-7 | p = 6.19E-7 | β = 0.24  p = 4.00E-9 | p = 1.31E-8 |
| Clusterin | β = 6.74  p = 0.03 | p = 0.11 | β = 0.17  p = 1.58E-9 | p = 2.14E-9 | β = 0.11  p = 1.23E-4 | p = 1.57E-4 | β = 0.15  p = 3.04E-4 | p = 3.89E-4 |
| hFatty Acid-Binding Protein | β = -3.73  p = 0.24 | p = 0.37 | β = 0.26  p = 6.73E-22 | p = 5.16E-21 | β = 0.22  p = 7.28E-16 | p = 1.67E-14 | β = 0.31  p = 1.39E-14 | p = 3.20E-13 |
| Lectin-Like Oxidized LDL Receptor 1 | β = 4.95  p = 0.12 | p = 0.23 | β = 0.23  p = 4.35E-16 | p = 1.67E-15 | β = 0.15  p = 2.80E-7 | p = 6.69E-7 | β = 0.22  p = 1.19E-7 | p = 3.03E-7 |
| Angiotensin-Converting Enzyme | β = 4.37  p = 0.16 | p = 0.28 | β = 0.19  p = 7.33E-12 | p = 1.20E-11 | β = 0.13  p = 1.26E-6 | p = 2.41E-6 | β = 0.18  p = 9.31E-6 | p = 1.37E-5 |
| Tissue Factor | β = 0.99  p = 0.75 | p = 0.75 | β = 0.28  p = 3.11E-26 | p = 7.16E-25 | β = 0.19  p = 1.97E-12 | p = 2.27E-11 | β = 0.30  p = 3.81E-14 | p = 4.38E-13 |
| Chromogranin-A | β = 2.93  p = 0.34 | p = 0.46 | β = 0.24  p = 1.77E-20 | p = 1.02E-19 | β = 0.17  p = 1.31E-10 | p = 7.54E-10 | β = 0.25  p = 1.11E-10 | p = 4.28E-10 |
| Cystatin-C | β = -2.51  p = 0.43 | p = 0.52 | β = -0.27  p = 8.65E-24 | p = 9.95E-23 | β = -0.18  p = 2.79E-11 | p = 2.14E-10 | β = -0.28  p = 3.26E-12 | p = 2.50E-11 |
| Trefoil Factor 3 | β = 7.10  p = 0.03 | p = 0.11 | β = 0.15  p = 1.77E-6 | p = 2.14E-6 | β = 0.13  p = 1.33E-5 | p = 1.91E-5 | β = 0.12  p = 7.49E-3 | p = 8.62E-3 |